Susquehanna Upgrades Simcere Pharmaceutical Group (SCR) to Positive; Raises FY10-12 Estimates
Tweet Send to a Friend
Susquehanna upgrades Simcere Pharmaceutical Group (NYSE: SCR) from Neutral to Positive. Price target $11.
Susquehanna analyst says, "We recently had ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Susquehanna analyst says, "We recently had ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
